株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

プレフィルドシリンジ市場 (第3版) 2015-2025年

Prefilled Syringes Market (3rd Edition), 2015 - 2025

発行 ROOTS ANALYSIS 商品コード 283286
出版日 ページ情報 英文 360 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
プレフィルドシリンジ市場 (第3版) 2015-2025年 Prefilled Syringes Market (3rd Edition), 2015 - 2025
出版日: 2015年06月29日 ページ情報: 英文 360 Pages
概要

当レポートでは、プレフィルドシリンジ (薬液充填済み注射器) 市場の規模と競合分析、製品の基本的概要、およびセグメント別の動向などをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 プレフィルドシリンジのイントロダクション

  • 本章の概要
  • プレフィルドシリンジの歴史
  • 従来型の注射装置に勝るプレフィルドシリンジのメリット
  • プレフィルドシリンジのコンポーネント
  • プレフィルドシリンジの分類
  • プレフィルドシリンジ設計の重要な特性
  • 市販のプレフィルドシリンジシステム
  • プレフィルドシリンジの技術開発

第4章 針刺し事故

  • 本章の概要
  • 事故とコスト負担
  • 針刺し事故防止の政府法案
  • プレフィルドシリンジメーカーが用いる安全メカニズム

第5章 成長の促進因子

  • 本章の概要
  • 自己注射患者数の増加
  • 慢性疾患発症率の増加
  • 患者統計の変化
  • 生物製剤・バイオシミラーの成長
  • プレフィルドシリンジの需要を促進する医薬品戦略の変化
  • オートインジェクター/ペン型インジェクター
    • プレフィルドシリンジとオートインジェクターのコンバージェンス
    • ペン型インジェクター vs. オートインジェクター

第6章 プレフィルドシリンジにおいて利用可能な製品

  • 本章の概要
  • プレフィルド形態で承認された薬
  • プレフィルド形態の主要薬剤 (売上別)
    • ケーススタディ: Humira (Adalimumab), AbbVie/エーザイ
    • ケーススタディ:Enbrel (Etanercept), Amgen/Pfizer/武田薬品工業
    • Copaxone (Glatiramer Acetate), Teva Pharmaceuticals
  • プレフィルド形態で利用可能なその他の薬剤
  • パイプライン製品
  • 利用可能な薬剤:治療クラス別
    • 抗リウマチ薬
    • 多発性硬化症 (MS)
    • 抗ウィルス薬
    • 抗凝固剤
    • ワクチン市場
    • 抗糖尿病市場
  • プレフィルドシリンジで利用可能な造影剤

第7章 プレフィルドシリンジの近年の開発動向・用途

  • 本章の概要
  • 凍結乾燥薬剤のためのプレフィルドシリンジ

第8章 プレフィルドシリンジメーカー

  • 本章の概要
  • 競合情勢マッピング
  • 主要メーカー
  • Becton Dickinson (BD)
  • Gerresheimer
  • ニプロ
  • SCHOTT
  • Nuova Ompi
  • その他のプレフィルドシリンジメーカー
  • West Pharmaceutical Services, Inc.
  • Unilife Corporation
  • Vetter Pharma
  • Aguettant

第9章 PFS (プレフィルドシリンジ) コンポーネントメーカー

  • 本章の概要
  • West Pharmaceutical Services, Inc.
  • Datwyler
  • Aptar Stelmi

第10章 世界のペン型インジェクター・オートインジェクターメーカー

  • 本章の概要
  • Ypsomed Holding AG
  • Scandinavian Health Limited (SHL) Group
  • Bespak
  • Owen Mumford
  • DALI Medical Devices/Elcam Medical
  • 将来のインジェクション技術
  • ペン型インジェクター・オートインジェクターを提供するその他の企業

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 プレフィルドシリンジシステムの主要地域市場

  • 本章の概要
  • 米国のプレフィルドシリンジ市場
  • 欧州のプレフィルドシリンジ市場
  • 中国のプレフィルドシリンジ市場
  • 中国のプレフィルドシリンジメーカー
  • 日本のプレフィルドシリンジ市場
  • 日本のプレフィルドシリンジメーカー
  • インドのプレフィルドシリンジ市場
  • インドのプレフィルドシリンジメーカー
  • インドネシアのプレフィルドシリンジ市場

第13章 世界のプレフィルドシリンジ市場予測

  • 本章の概要
  • 調査範囲・調査手法
  • 世界市場規模・予測
    • ワクチン用プレフィルドシリンジ
    • 薬剤用プレフィルドシリンジ
    • 希釈剤プレフィルドシリンジ、フラッシュプレフィルドシリンジおよび造影剤用プレフィルドシリンジ
    • 市場全体の規模
  • 地域の市場規模・予測:米国、欧州、アジア太平洋およびその他の地域

第14章 インタビュー記録

  • 本章の概要
  • West Pharmaceutical Services, Inc.
  • Oval Medical Technologies
  • Revolutions Medical

第15章 結論

第16章 付録1:表形式データ

第17章 付録2:企業および組織リスト

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10041

Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, auto-injectors, pen injectors and needle free systems. These modern devices have become preferred devices for parenteral administration of drugs, mainly used for treatment of chronic conditions requiring patients to self-administer medication several times a week.

The origins of prefilled syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins in Europe. These have been around for more than three decades and are used in all major therapeutic classes for injectable drug formulations. Owing to their numerous benefits over conventional delivery systems and the growing application areas, prefilled syringes have now become indispensable in the medical fraternity. This is evident from our research during which we identified a large number of instances where prefilled syringes are being used to administer vaccines, anticoagulants, multiple sclerosis drugs, anti-arthritic drugs, anti-anaemic drugs and drugs from several other classes. Further, these syringes are also being used as primary drug containers in pen and auto-injectors. In addition, prefilled diluent syringes and flush syringes are also increasingly finding wider adoption. With pharma companies viewing prefilled syringes as a potent life cycle management tool, the pipeline is rich and growing rapidly.

The rising demand has also driven the manufacturers to introduce improvements in technology related to the material of prefilled syringes and lubrication (to reduce leachables and extractables). These developments will aid an increasing number of biologic drugs to reach the market. Additionally, the companies have developed multi-chamber prefilled syringes for use with lyophilised drugs. In our research, we have looked at how these developments and other factors are shaping the market and discussed the factors creating opportunities for various stakeholders in the market.

Synopsis:

The ‘Prefilled Syringes Market (3rd Edition)' report provides a comprehensive analysis of the state of prefilled syringes market. Starting with the basic introduction to prefilled syringes, their origin, components and manufacturing material, this report talks about needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes. A key objective of the report is to enumerate various prefilled syringe systems available in the market, drugs available in these syringes and the corresponding market potential across different geographical regions. We have discussed various historical/likely future trends which have shaped/will shape the US, European, Japanese, Chinese, Indian and rest of the world markets. We have also included a detailed overview of biologics and biosimilars, one of the primary growth drivers of this market.

The study focuses on analysing the existing market size and potential future growth of these drug delivery devices across different drug therapeutic classes and regions. The forecast, over the next ten years, has been presented both in terms of volume (number of units) and value (USD billion). It takes into account the likely price variation which will occur as a result of mass adoption and increased competition. Owing to uncertainty surrounding the adoption of prefilled syringes in newer drug classes (which are currently in pipeline); we have also done a multi-variate sensitivity analysis to understand the various market growth scenarios.

In an effort to identify existing gaps and future opportunities, we have discussed the leading global prefilled syringe manufacturers in the industry, analysed their product portfolio and the likely future developments driven by these companies. We have put special emphasis and provided details on local manufacturers which are very well positioned to take advantage of the emerging big home consumer markets. In addition, we have profiled some important prefilled syringe component manufacturers as well as manufacturers of self-injection systems that use prefilled syringes as primary drug container.

The market forecasts across different segments and regions have been presented till 2025. 2014 is the base year; actual figures have been sourced and analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.

Example Highlights

  • 1. Over 65 drugs and vaccines are already available in prefilled syringes across different therapeutic classes. In addition, there are several more in clinical pipeline which are being tested in prefilled syringes.
  • 2. Vaccines and anti-coagulants are examples of well-established applications. The emergence of biologics will be a major growth driver; growth in the long-term will be fuelled by pipeline drugs and the rising adoption in developing markets.
  • 3. Increasing number of suppliers now provide ready to fill/ sterile prefilled syringes, which make up more than 80% of the prefilled syringes market. The integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
  • 4. Companies are constantly innovating technology for improving the compatibility of syringes with biologics to provide better extractables and leachables profiles. In addition, improved ergonomic designs now offer comfortable administration of drugs.
  • 5. The market is highly consolidated and is currently dominated by key global players such as Becton Dickinson, Gerresheimer, Mglas AG, SCHOTT and Nuova Ompi. Other companies, which are relatively new entrants (e.g. West Pharmaceutical Services, Unilife, Vetter Pharma and Aguettant), are likely to foster more innovation. Apart from these companies, companies such as Datwyler and Aptar Stelmi are well-known suppliers of various components of prefilled syringes.
  • 6. The global prefilled syringes market is likely to grow at a compounded annual growth rate (CAGR) of 4.3% between 2014 to 2025.Developed markets of the US and EU currently account for 80% of the market. With increasing adoption in Asia Pacific and rest of the world markets, this domination is likely to gradually decline.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

The sales/revenue data are actual sales as reported in the company annual reports and represent full year sales for respective fiscal years.

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of prefilled syringes market.

Chapter 3 provides a general overview of prefilled syringes including their origin, components, types and manufacturing material. We have listed the major prefilled syringes currently available and presented a detailed market landscape. The chapter also discusses the technological advancements that have led to the evolution of the industry over the last several years.

Chapter 4 highlights the issue of needlestick injuries and various preventive laws worldwide which have put the focus on safety features in prefilled syringes.The chapter also discusses various manufacturers of safety systems including add-on devices and integrated safety prefilled syringes.

Chapter 5 highlightsthe key growth drivers of prefilled syringes market. These include the growing trend of self-injection, rise in chronic diseases, changing patient demographics and growth of biologics.

Chapter 6 highlights the leading therapeutic drug classes available in prefilled syringes. It also provides a list of top nine drugs in prefilled syringes with detailed case studies on Humira, Enbrel and Copaxone. For each therapeutic class, we have identified the drugs available in prefilled syringes and estimated patent expiry; we have also looked at the biosimilars currently in development.

Chapter 7 details the recent technological developments and their applications in prefilled syringes market focusing on syringes being manufactured for lyophilised drugs in dual / multi chambered system for drug reconstitution.

Chapter 8 provides profiles of the key manufacturers of prefilled syringes. Each company profile includes information on financial performance, geographical presence, marketed devices, recent developments and an informed future outlook. Key players covered in this section include (in alphabetical order) Aguettant, Becton Dickinson, Gerresheimer, Nipro Corporation, Nuova Ompi, SCHOTT, Unilife, Vetter Pharma and West Pharmaceuticals.

Chapter 9 highlights various prefilled syringe component manufacturers and their product portfolio. Key players covered in this section include Aptar Stelmi, Datwyler and West Pharmaceuticals.

Chapter 10 discusses detailed profiles of major pen and auto-injector manufacturers which use prefilled syringes as primary drug container providing information on their financial performance, product portfolio and recent developments. Key players covered in this section include (in alphabetical order) Becton Dickinson, Bespak, DALI Medical, Future Injection Technologies, Owen Mumford, SHL Group, Unilife, West Pharmaceuticals and Ypsomed.

Chapter 11 provides the SWOT analysis of prefilled syringes market giving strategic insights on the major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that can negatively impact the growth.

Chapter 12 analyses the regional markets (the US, Europe, China, Japan, India and RoW) for prefilled syringes. For each region, the chapter focuses on the market size and various technological, commercial and regulatory details; in addition to the global players which have been profiled in earlier sections, this chapter includes profiles of the key regional players in Chinese, Japanese and Indian markets.

Chapter 13 provides a detailed description of the likely evolution of prefilled syringes market. We have adopted a detailed ‘;top down' approach, backed by robust data and credible inputs from primary research, to identify the likely size of the market, both in terms of volume (number of units) and value (in USD billion).

Chapter 14 is a collection of interview transcripts. For the purposes of our study, we contacted a number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry.

Chapter 15 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO PREFILLED SYRINGES

  • 3.1. Chapter Overview
  • 3.2. History of Prefilled Syringes
  • 3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
    • 3.3.1. Benefits for Healthcare Professionals and End Users
    • 3.3.2. Benefits for Manufacturers
    • 3.3.3. Shift of Existing Formulations to Prefilled Syringes
  • 3.4. Prefilled Syringe Components
  • 3.5. Classification of Prefilled Syringes
    • 3.5.1. Manufacturing Material of Barrel
    • 3.5.2. Glass: Historical Material of Choice
      • 3.5.2.1. Limitations of Glass Prefilled Syringes
      • 3.5.2.2. Addressing the Limitations of Glass Prefilled Syringes
      • 3.5.2.3. Advantages of Plastic Prefilled Syringes
      • 3.5.2.4. Slow Adoption of Plastic Prefilled Syringes
      • 3.5.2.5. Factors Likely to Drive the Use of Plastic Prefilled Syringes
    • 3.5.3. Single-Chamber and Dual-Chamber
    • 3.5.4. Type of Needle
    • 3.5.5. Type of Processing
  • 3.6. Critical Attributes of a Prefilled Syringe Design
  • 3.7. Prefilled Syringe Systems Available in the Market
    • 3.7.1 Glass Prefilled Syringes
    • 3.7.2 Plastic Prefilled Syringes
  • 3.8. Technological Developments in Prefilled Syringes

4. NEEDLESTICK INJURIES

  • 4.1. Chapter Overview
  • 4.2. Incidence and Cost Burden
  • 4.3. Government Legislation for Needlestick Injury Prevention
  • 4.4. Safety Mechanism Used by Prefilled Syringe Manufacturers
    • 4.4.1. Safety Systems: Add-on Devices
    • 4.4.2. Safety Systems: Integrated Devices

5. GROWTH DRIVERS

  • 5.1. Chapter Overview
  • 5.2. Increase in Number of Self-injecting Patients
  • 5.3. Increase in Incidence of Chronic Diseases
  • 5.4. Changing Patient Demographics
  • 5.5. Growth of Biologics and Biosimilars
  • 5.6. Changing Pharmaceutical Strategies Driving Demand for Prefilled Syringes
  • 5.7. Auto-Injectors / Pen-Injectors
    • 5.7.1. Convergence of Prefilled Syringes with Auto-injectors
    • 5.7.2. Pen-injectors vs. Auto-injectors

6. PRODUCTS AVAILABLE IN PREFILLED SYRINGES

  • 6.1. Chapter Overview
  • 6.2. Drugs Approved in Prefilled Format in 2013-2015
  • 6.3. Leading Drugs (By Sales) in Prefilled Format, 2014
    • 6.3.1. Case Study: Humira (Adalimumab), AbbVie/Eisai
      • 6.3.1.1. Indications and Dosage Forms
      • 6.3.1.2. Humira: Launched in Prefilled Syringe
    • 6.3.2. Case Study: Enbrel (Etanercept), Amgen/Pfizer/Takeda
      • 6.3.2.1. Indications and Dosage Forms
      • 6.3.2.2. Enbrel: Move from Vial to Syringes
    • 6.3.3. Copaxone (Glatiramer Acetate), Teva Pharmaceuticals
      • 6.3.3.1. Indications and Dosage Forms
      • 6.3.3.2. Copaxone: Move from Vial to Syringes
  • 6.4. Other Drugs Available in Prefilled Format, 2014
  • 6.5. Pipeline Products
  • 6.6. Drugs Available by Therapeutic Classes
    • 6.6.1. Anti-rheumatics
      • 6.6.1.1. Approved Injectables
      • 6.6.1.2. Biosimilars
    • 6.6.2. Multiple Sclerosis (MS)
      • 6.6.2.1. Approved Injectables
      • 6.6.2.2. Biosimilars
    • 6.6.3. Anti-virals, 2015
      • 6.6.3.1. Approved Injectables, 2015
      • 6.6.3.2. Biosimilars
    • 6.6.4. Anticoagulants, 2015
      • 6.6.4.1. Approved Injectables, 2015
      • 6.6.4.2. Biosimilars/Generics
    • 6.6.5. Vaccines Market, 2015
    • 6.6.6. Anti-Diabetes Market, 2015
      • 6.6.6.1. Insulin Market, 2015
      • 6.6.6.2. Approved Injectables
      • 6.6.6.3. Biosimilars
  • 6.7. Contrast Agents Available in Prefilled Syringes

7. RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES

  • 7.1. Chapter Overview
  • 7.2. Prefilled Syringes for Lyophilised Drugs
    • 7.2.1. Prefilled Diluent Syringes
      • 7.2.1.1. Lyophilised Drugs Available in Prefilled Diluent Syringe Systems
    • 7.2.2. Dual/Multi-Chamber Syringes
      • 7.2.2.1. Lyophilised Drugs Available in Dual/Multi-Chamber Prefilled Syringe
      • 7.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilised Drugs
    • 7.2.3. Prefilled Reconstitution Systems for Lyophilised Drugs

8. MANUFACTURERS OF PREFILLED SYRINGE

  • 8.1. Chapter Overview
  • 8.2. Mapping the Competitive Landscape
  • 8.3. Leading Global Prefilled Syringes Manufacturers
  • 8.4. Becton Dickinson (BD)
    • 8.4.1 Company Overview
    • 8.4.2. Financial Performance, 2010-2014
    • 8.4.3. Glass Prefilled Systems
      • 8.4.3.1. BD Hypak Syringe System
      • 8.4.3.2. Luer Products
      • 8.4.3.3. Staked Needle Products
      • 8.4.3.4. BD Neopak Syringe System
    • 8.4.4. Plastic Prefilled Systems
      • 8.4.4.1. BD Sterifill Syringe Systems
    • 8.4.5. Other Prefilled Delivery Systems
      • 8.4.5.1. BD Uniject
      • 8.4.5.2. BD Soluvia
    • 8.4.6. BD Prefilled Technology Solutions
    • 8.4.7. Recent Developments
      • 8.4.7.1. Deals and Agreements
      • 8.4.7.2. Expanding Prefilled Syringe Portfolio
      • 8.4.7.3. Entering the Generic Business
    • 8.4.8. Future Outlook
  • 8.5. Gerresheimer
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance, 2010- 2014
    • 8.5.3. Glass Prefilled Systems
      • 8.5.3.1. Gx Glass Syringes
    • 8.5.4. Plastic Prefilled Systems
      • 8.5.4.1. ClearJect Plastic Syringes
    • 8.5.5. Self-Injection Devices
    • 8.5.6. Prefilled Technology Solutions
    • 8.5.7. Recent Developments
      • 8.5.7.1. Expansion of Product Portfolio
      • 8.5.7.2. Expansion of Manufacturing Capacity for RTF Syringes
      • 8.5.7.3. Medical Plastic Systems Capacity Expansion
      • 8.5.7.4. Growing Interest in Emerging Economies
    • 8.5.8. Future Outlook
  • 8.6. Nipro Corporation (acquired MGlas AG)
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance, 2010-2014
    • 8.6.3. Glass Prefilled Systems
    • 8.6.4. Plastic Prefilled Systems
    • 8.6.5. Recent Developments
    • 8.6.6. Future Outlook
  • 8.7. SCHOTT
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance, 2014
    • 8.7.3. Glass Prefilled Systems
      • 8.7.3.1. syriQ (previously Forma 3s) Glass Syringes
      • 8.7.3.2. syriQInJentle Syringes
    • 8.7.4. Plastic Prefilled Systems
      • 8.7.4.1. TopPac Polymer Syringes
    • 8.7.5. Recent Developments
      • 8.7.5.1. TopPac Syringe System for Sensitive Drugs (SD)
      • 8.7.5.2. TopPac Syringe System for Highly Viscous Drugs
      • 8.7.5.3. TopPac 20 ml Syringe System for Infusion Therapy
      • 8.7.5.4. Rebranding of the Glass PFS
      • 8.7.5.5. Looking To Grow in the Pharma EmergingMarkets (Brazil, China, India, Indonesia and Russia)
      • 8.7.5.6. Production Facility in the US and EU Likely to Provide Advantage
    • 8.7.6. Future Outlook
  • 8.8. Nuova Ompi
    • 8.8.1. Company Overview
    • 8.8.2. Glass Prefilled Systems
      • 8.8.2.1. EZ-fill Syringes
    • 8.8.3. Recent Developments
      • 8.8.3.1. New Corporate Branding
      • 8.8.3.2. Capacity Expansion Across the Glass Division
  • 8.9. Other Prefilled Syringe Manufacturers
  • 8.10. West Pharmaceutical Services, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance, 2010 - 2014
    • 8.10.3. Plastic Prefilled Systems
      • 8.10.3.1. Daikyo Crystal Zenith (CZ) RU PFS
    • 8.10.4. Drug Reconstitution Systems
    • 8.10.5. Prefilled Technology Solutions
    • 8.10.6. Recent Developments
      • 8.10.6.1. Advancing the Growth of CZ Syringes
      • 8.10.6.2. Looking To Grow in the Pharmerging Markets (Brazil, China, India)
      • 8.10.6.3. Manufacturing Expansion
    • 8.10.7. Future Outlook
  • 8.11. Unilife Corporation
    • 8.11.1. Company Overview
    • 8.11.2. Financial Performance, 2011- 2014
    • 8.11.3. Glass PFS
      • 8.11.3.1. Unifill Syringes
      • 8.11.3.2. EZ-Mix Syringes
    • 8.11.4. Wearable Injector Platform
    • 8.11.5. Ocular Delivery Systems
    • 8.11.6. Novel Delivery Systems
    • 8.11.7. Supply Agreements
      • 8.11.7.1. Partnership with AbbVie
      • 8.11.7.2. Partnership with Global Pharma Company
      • 8.11.7.3. Partnership with Novartis
      • 8.11.7.4. Partnership with Hikma
      • 8.11.7.5. Partnership with Sanofi
      • 8.11.7.6. Partnership with Biodel
    • 8.11.8. Recent Developments
      • 8.11.8.1. Expansion
      • 8.11.8.2. Fundings
    • 8.11.9. Future Outlook
  • 8.12. Vetter Pharma
    • 8.12.1. Company Overview
    • 8.12.2. Lyo-Ject Glass PFS
    • 8.12.3. Recent Developments
      • 8.12.3.1. Capacity Expansion
      • 8.12.3.2 Collaboration with West Pharmaceuticals
    • 8.12.4. Future Outlook
  • 8.13. Aguettant
    • 8.13.1. Company Overview
      • 8.13.1.1. Aguettant Prefilled Syringe
      • 8.13.1.2. Aguettant Self Injector Pen
    • 8.13.2. Recent Developments

9. PFS COMPONENT MANUFACTURERS

  • 9.1. Chapter Overview
  • 9.2. West Pharmaceutical Services, Inc.
    • 9.2.1. PFS Components
      • 9.2.1.1. Plungers
      • 9.2.1.2. Needle Shield and Tip Cap
      • 9.2.1.3. Backstops
    • 9.2.2. Manufacturing of PFS Components
  • 9.3. Datwyler
    • 9.3.1. Financial Performance, 2010- 2014
    • 9.3.2. PFS Components
      • 9.3.2.1. Plungers
      • 9.3.2.2. Needle Shields and Tip Caps
    • 9.3.3. Manufacturing of PFS Components
  • 9.4. Aptar Stelmi
    • 9.4.1. Financial Performance,2014
    • 9.4.2. PFS Components
      • 9.4.2.1. Plungers
      • 9.4.2.2. Needle Sheilds
      • 9.4.2.3. Tip Caps
      • 9.4.2.4. Stoppers

10. GLOBAL PEN AND AUTO-INJECTOR MANUFACTURERS

  • 10.1. Chapter Overview
  • 10.2. Ypsomed Holding AG
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance, 2010- 2014
    • 10.2.3. Product Portfolio
      • 10.2.3.1. Auto-Injectors
    • 10.2.4. Recent Developments
      • 10.2.4.1. Geographical Expansion
      • 10.2.4.2. Collaborations
    • 10.2.5. Development Strategy
  • 10.3. Scandinavian Health Limited (SHL) Group
    • 10.3.1. Company Overview
    • 10.3.2. Product Portfolio
      • 10.3.2.1. Auto-injectors
    • 10.3.3. Recent Developments
      • 10.3.3.1. Capacity Expansion
      • 10.3.3.2. Collaborations
    • 10.3.4. Development Strategy
  • 10.4. Bespak
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance, 2010- 2014
    • 10.4.3. Product Portfolio
      • 10.4.3.1. Auto-injectors
    • 10.4.4. Recent Developments
      • 10.4.4.1. Collaborations
    • 10.4.5. Future Outlook
  • 10.5. Owen Mumford
    • 10.5.1. Company Overview
    • 10.5.2. Product Portfolio
      • 10.5.2.1. Auto-injectors
  • 10.6. DALI Medical Devices/Elcam Medical
    • 10.6.1. Company Overview
    • 10.6.2. Product Portfolio
      • 10.6.2.1. DALI Products
      • 10.6.2.2. Elcam Products
  • 10.7. Future Injection Technologies
    • 10.7.1. Company Overview
    • 10.7.2. Product Portfolio
  • 10.8. Other Companies Offering Pen and Auto Injectors
    • 10.8.1. Unilife
    • 10.8.2. West Pharmaceutical Services
    • 10.8.3. Becton Dickinson

11. SWOT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Strengths
    • 11.2.1. Ease of Use
    • 11.2.2. Elimination of Medication Errors
    • 11.2.3. High Incidence of Blood-borne Pathogen Transmission
    • 11.2.4. Economic Advantages
    • 11.2.5. Life Cycle Management
  • 11.3. Weaknesses
    • 11.3.1. Manufacturing Complexities
    • 11.3.2. Elevated Packaging Costs
    • 11.3.3. Product Stability
    • 11.3.4. Air Bubbles During Filling
  • 11.4. Opportunities
    • 11.4.1. Use of Prefilled Syringes in Advanced Delivery Devices
    • 11.4.2. Innovation in Prefilled Syringes to Address Needlestick Injuries
    • 11.4.3. Geographic Expansion
    • 11.4.4. Useful in Vaccination Programmes
  • 11.5. Threats
    • 11.5.1. Material Compatibility Issues
    • 11.5.2. Recall of Prefilled Syringes
    • 11.5.3. Alternative Drug Delivery Devices

12. LEADING REGIONAL MARKETS FOR PREFILLED SYRINGE SYSTEMS, 2015 - 2025

  • 12.1. Chapter Overview
  • 12.2. The US Market for Prefilled Syringes, 2014
    • 12.2.1. Prefilled Syringes are Combination Products
    • 12.2.2. Regulation of Combination Products in the US
    • 12.2.3. Regulatory Approval of Prefilled Syringes in the US
    • 12.2.4. Trends in the US Prefilled Syringes Market
  • 12.3. European Market for Prefilled Syringes, 2014
    • 12.3.1. Combination Products in Europe
    • 12.3.2. Regulatory Approval of Prefilled Syringes in Europe
    • 12.3.3. Trends in the European Prefilled Syringe Market
      • 12.3.3.1. Europe is the Preferred Destination for Manufacturing Prefilled Syringes
  • 12.4. The Chinese Market for Prefilled Syringes, 2014
  • 12.5. Chinese Prefilled Syringe Manufacturers
    • 12.5.1. Shandong Weigao Group Pharmaceutical Packaging Company Ltd.: First Registered Manufacturer Of PFS In China Since 2005
      • 12.5.1.1. Financial Performance, 2014
      • 12.5.1.2. WeGo: Glass PFS
    • 12.5.2. Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
    • 12.5.3. Shandong Pharmaceutical Glass Co., Ltd.
    • 12.5.4. YangZhong Wealth Metal Co., Ltd.
    • 12.5.5. Youlyy Industrial Co., Ltd.
  • 12.6. The Japanese Market for Prefilled Syringes
    • 12.6.1. Regulation of Combination Products in Japan
    • 12.6.2. Primary Pharmaceutical Packaging Market in Japan
    • 12.6.3. State of the Market: Drugs and Companies
  • 12.7. Japanese Prefilled Syringe Manufacturers
    • 12.7.1. Terumo Corporation: Growing Y-o-Y Sales of Plastic PFS Indicates an Increasing Trend of a Shift from Glass PFS
      • 12.7.1.1. Company Overview
      • 12.7.1.2. Financial Performance, 2010- 2014
      • 12.7.1.3. Plajex: Plastic PFS
      • 12.7.1.4. Safety Devices: Add-On Devices
    • 12.7.2. Taisei Kako Co., Ltd.: Sales Tie-Up With Gerresheimer Bunde Has Facilitated Availability Of Plastic PFS To Worldwide Locations
      • 12.7.2.1. Company Overview
      • 12.7.2.2. VF-Syringe Glass PFS
      • 12.7.2.3. ClearJect Plastic Prefilled Syringes
      • 12.7.2.4. Fulject Plastic Prefilled Syringes
    • 12.7.3. ARTE CORPORATION: Manufacturing Single And Dual-Chambered PFS
      • 12.7.3.1. Company Overview
      • 12.7.3.2. Arte Prefillable Syringes
    • 12.7.4. J.O. Pharma Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd): Continually Expanding To Meet The Growing Demand For PFS
  • 12.8. Indian Market for Prefilled Syringes, 2014
  • 12.9. Indian Prefilled Syringe Manufacturers
    • 12.9.1. Roselabs Group: First Indian Company Manufacturing and Formulating Under One Roof
      • 12.9.1.1. Company Overview
      • 12.9.1.2. Rose-Fill Glass Prefilled Systems
      • 12.9.1.3. Rose-Fill Plastic Prefilled Systems
      • 12.9.1.4. Recent Developments
  • 12.10 Indonesian Market for Prefilled Syringes, 2014

13. GLOBAL PREFILLED SYRINGES MARKET FORECAST, 2015 - 2025

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Global Market Size and Forecast
    • 13.3.1. Prefilled Syringes for Vaccines
    • 13.3.2. Prefilled Syringes for Drugs
      • 13.3.2.1. Prefilled Syringes for Anticoagulants
      • 13.3.2.2. Prefilled Syringes for Diabetes
      • 13.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
      • 13.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
      • 13.3.2.5. Prefilled Syringes for Anti-Anaemic Drugs
      • 13.3.2.6. Prefilled Syringes for Other Drug Classes
    • 13.3.3. Prefilled Diluent Syringes, Prefilled Flush Syringes and Prefilled Syringes for Contrast Agents
    • 13.3.4. Overall Global Market Size
  • 13.4. Regional Market Size and Forecast: US, Europe, Asia Pacific and Rest of the World

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. West Pharmaceutical Services, Inc.
  • 14.3. Oval Medical Technologies
  • 14.4. Revolutions Medical

15. CONCLUSION

  • 15.1. The Shift from Vials to Prefilled Syringes
  • 15.2. Plastic Syringes to Outperform Glass Syringes
  • 15.3. Consolidated Market with Five Established Players; New Entrants Driving Innovation
  • 15.4. Growth of Biologics, Rising Trend of Self-Medication and Many Other Factors will Fuel the Growth
  • 15.5. Slow Growth Expected Over the Coming Decade
  • 15.6. Despite Being Full of Opportunities, Challenges Remain

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures:

  • Figure 2.1: Market Evolution: 2015, 2020, 2025 (Number of Units)
  • Figure 2.2: Market Landscape: Geographical Trends
  • Figure 3.1: Glass Prefilled Syringes: Advantages and Disadvantages
  • Figure 3.2: Plastic Prefilled Syringes: Advantages and Disadvantages
  • Figure 3.3 Critical Design Parameters of Prefilled Syringes
  • Figure 3.4: Prefilled Syringes: Market Landscape by Manufacturer
  • Figure 3.5: Technological Evolutions of Prefilled Syringes
  • Figure 5.1: Global Prevalence of Diabetes: Distribution by Countries, 2013 (Million,%)
  • Figure 5.2: Numbers of Biologics Approved by the USFDA, 2009-2015
  • Figure 5.3: Top Selling Biologics: Estimated Patent Expiry
  • Figure 6.1: Sales of Leading Drugs Available in Prefilled Syringes, 2014 (USD Million)
  • Figure 6.2: Humira: Approval Timeline for Various Indications in the US & EU
  • Figure 6.3: Humira: Approval Timeline for Various Dosage Forms in the US & EU
  • Figure 6.4: Humira: Global Sales, 2003-2014 (USD Million)
  • Figure 6.5: Enbrel: Approval Timeline for Various Indications in the US & EU
  • Figure 6.6: Enbrel: Approval Timeline for Various Dosage Forms in the US & EU
  • Figure 6.7: Enbrel: US & Canada Sales, 2002-2014 (USD Million)
  • Figure 6.8: Enbrel: Outside US and Canada (EU, Japan) Sales, 2010-2014 (USD Million)
  • Figure 6.9: Copaxone: Sales, 2001-2014 (USD Million)
  • Figure 6.10: Copaxone: Unit Sales, 2000-2008: Distribution by Vials and Prefilled Syringes (Million)
  • Figure 6.11: Numbers of Biosimilars in Development for Anti-Rheumatics
  • Figure 6.12: Numbers of Biosimilars in Development for Multiple Sclerosis Drugs
  • Figure 6.13: Numbers of Biosimilars in Development for Anti-Virals
  • Figure 6.14: Numbers of Biosimilars in Development for Anticoagulants
  • Figure 6.15: Numbers of Biosimilars in Development for Anti-Diabetes
  • Figure 8.1: Glass PFS: Product Landscape Analysis
  • Figure 8.2: Polymer PFS: Product Landscape Analysis
  • Figure 8.3: Becton Dickinson Medical: Sales, 2010-2014 (USD, Billion)
  • Figure 8.4: Becton Dickinson Medical: Sales by Sub-Segments, 2014 (USD Billion, %)
  • Figure 8.5: Gerresheimer: Sales, 2010-2014 (EUR Million)
  • Figure 8.6: Gerresheimer: Sales by Business Divisions, 2014 (EUR Million, %)
  • Figure 8.7: Gerresheimer: Sales by Region, 2011-2014 (EUR Million)
  • Figure 8.8: Nipro Corporation: Sales, 2010-2014 (YEN Billion)
  • Figure 8.9: Nipro Corporation: Sales by Business Divisions, FY 2013/14 (YEN Billion, %)
  • Figure 8.10: Nipro Corporation: Global Sales by Region, FY 2013/14 (YEN Billion, %)
  • Figure 8.11: Nipro Corporation: Sales by Domestic Market, 2010-2014 (YEN Billion)
  • Figure 8.12: SCHOTT: Sales, FY 2012/13- FY2013/14 (EUR Million)
  • Figure 8.13: SCHOTT: Sales by Business Divisions, FY 2013/14 (EUR Million, %)
  • Figure 8.14: SCHOTT: Sales by Region, FY 2013/14 (EUR Million, %)
  • Figure 8.15: West Pharmaceutical Services: Sales, 2010-2014 (USD Million)
  • Figure 8.16: West Pharmaceutical Services: Sales by Business Divisions, 2014 (USD Million, %)
  • Figure 8.17: West Pharmaceutical Services: Delivery Systems Sales, 2010-2014 (USD Million)
  • Figure 8.18: West Pharmaceutical Services: Sales by Domestic Market, 2010-2014 (USD Million)
  • Figure 8.19: West Pharmaceutical Services: Global Sales by Region, 2014 (USD Million, %)
  • Figure 8.20: Unilife Corporation: Sales, FY 2010/11-2013/14 (USD Million)
  • Figure 9.1: Datwlyer Group: Sales, 2010-2014 (CHF, Million)
  • Figure 9.2: Datwlyer Group: Sales by Business Divisions, 2014 (CHF, Million)
  • Figure 9.3: Aptar Stelmi: Sales by Business Divisions, 2014 (USD, Million)
  • Figure 10.1: Ypsomed Sales, 2010-2014 (CHF Million)
  • Figure 10.2: Ypsomed: Sales by Business Divisions, FY 2014/15 (CHF Million, %)
  • Figure 10.3: Ypsomed: Cartridge Based Pen-Injectors
  • Figure 10.4: Ypsomed: Cartridge Based Dual Chamber Pen-Injectors
  • Figure 10.5: Ypsomed: Prefilled Syringe or Cartridge Based Auto-Injectors
  • Figure 10.6: SHL Medical: Cartridge Based Systems
  • Figure 10.7: SHL Medical: Prefilled Syringe Based Auto-Injectors
  • Figure 10.8: Bespak: Sales, 2009-2013 (GBP, Million)
  • Figure 10.9: Bespak Injectables: Cartridge Based Systems
  • Figure 10.10: Bespak: Lila Platform Products
  • Figure 10.11: Bespak Injectables: Prefilled Syringe Based Auto-Injectors
  • Figure 10.12: Owen Mumford: Cartridge-Based Injection Pens
  • Figure 10.13: Owen Mumford: Prefilled Syringe Based Auto-Injectors
  • Figure 10.14: DALI: Auto-injector Product Portfolio
  • Figure 10.15: Elcam Medical: Auto-injector Product Portfolio
  • Figure 10.16: Future Injection Technologies: Product Portfolio
  • Figure 10.17: Becton Dickinson: Cartridge Based Systems
  • Figure 11.1: Common Medication Errors (%)
  • Figure 11.2: Common Sources of Medication Errors (%)
  • Figure 11.3: Prefilled Syringe Recalls, 2003-2015: Distribution by Type of Issue
  • Figure 12.1: The US Vaccines Market: By Type of Packaging (%)
  • Figure 12.2: European Vaccines Market: By Type of Packaging (%)
  • Figure 12.3: Domestic Prefilled Syringe Manufacturers in China: Annual Production Capacities, 2012 (Million Units)
  • Figure 12.4: Shandong Weigao: Prefilled Syringes Revenue (RMB Million), 2010-2014
  • Figure 12.5: Shandong Weigao: Revenue by Product Category (RMB Million, %), 2014
  • Figure 12.6: Japanese Prefilled Syringes Market: By Material of Barrel (%)
  • Figure 12.7: Terumo Corporation: Sales, 2010 - 2014 (Yen Billion)
  • Figure 12.8: Terumo Corporation: Sales by Business Divisions, FY 2014/15 (YEN Billion, %)
  • Figure 12.9: Terumo Corporation: Sales by Region, FY 2014/15 (YEN Billion, %)
  • Figure 13.1: Prefilled Syringes Price Curve, 2015 - 2025 (USD per unit)
  • Figure 13.2: Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.3: Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.4: Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.5: Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.6: Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.7: Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.8: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.9: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.10: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.11: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.12: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.13: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.14: Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.15: Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.16: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.17: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.18: Global Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.19: Global Prefilled Syringes, Units Growth by Category, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.20: Global Prefilled Syringes, Sales Forecasted, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.21: Global Prefilled Syringes, Sales Growth by Category, 2014 - 2024 (Base Scenario, USD Million)
  • Figure 13.22: Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Figure 13.23: Regional Prefilled Syringes, ForecastedSales, 2015 - 2025 (Base Scenario, USD Million)
  • Figure 13.24: Prefilled Syringes Market, Distribution by Regions, 2015 - 2025 (%)
  • Figure 15.1: Prefilled Syringes Market: 2015, 2020 and 2025 (Units, Billions)
  • Figure 15.2: Prefilled Syringes Market: 2015, 2020, and 2025 (USD Billion)

List of Tables:

  • Table 3.1: Drugs: From Vials to Prefilled Syringe Systems, US
  • Table 3.2: Classification of Prefilled Syringes
  • Table 3.3: Advantages of Glass as Barrel Material
  • Table 3.4: Prefilled Glass Syringe Recalls
  • Table 3.5: Advantages of Plastic Polymers as Barrel Material
  • Table 3.6: Pharmaceutical Filling Lines - Process Flow by Type of Prefilled Syringe
  • Table 3.7: Prefilled Syringe Systems Available in the Market, 2015: A Comparison, By Manufacturer
  • Table 3.8: Glass Prefilled Syringes Available in the Market, 2015
  • Table 3.9: Plastic Prefilled Syringes Available in the Market, 2015
  • Table 4.1: List of Add-On Safety Device Manufacturers
  • Table 4.2: List of Integrated Prefilled Safety Device Manufacturers
  • Table 5.1: Population Over 65 in the US and Selected Countries in Europe, 2010, 2015 and 2020 (%)
  • Table 5.2: List of Auto-injector/Pen-injector Systems - Approved in 2013-2015
  • Table 5.3: List of Auto-injector/Pen-injector Systems (Using Prefilled Syringes) Available in the Market
  • Table 6.1: Drugs Approved in Prefilled Syringes, 2013-2015
  • Table 6.2: List of Other Drugs Sold in Prefilled Syringes
  • Table 6.3: List of Some Pipeline Drugs Using Prefilled Syringe Systems,
  • Table 6.4: Anti-Rheumatics Sales, 2014: Distribution by Leading Drugs (USD Million, %)
  • Table 6.5: Anti-Rheumatics Drugs Available in Prefilled Syringes, 2015
  • Table 6.6: Anti-Rheumatic Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 6.7: Multiple Sclerosis Sales, 2014: Distribution by Leading Drugs (USD Million, %)
  • Table 6.8: Multiple Sclerosis Drugs Available in Prefilled Syringes, 2015
  • Table 6.9: Multiple Sclerosis Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 6.10: Anti-Virals Sales, 2014: Distribution by Leading Drugs (USD Million, %)
  • Table 6.11: Anti-virals Available in Prefilled Syringes, 2015
  • Table 6.12: Anti-virals Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 6.13: Anticoagulants Sales, 2014: Distribution by Leading Drugs (USD Million, %)
  • Table 6.14: Anticoagulants Available in Prefilled Syringes, 2015
  • Table 6.15: Anticoagulants Available in Prefilled Format: Patent Expiry and Biosimilars/Generics Development
  • Table 6.16: Vaccines Sales, 2014: Distribution by Leading Vaccines (USD Million, %)
  • Table 6.17: Leading Vaccines Available in Prefilled Syringes, 2015
  • Table 6.18: Anti-Diabetes Market: Distribution by Leading Drugs, 2014 (USD Million, %)
  • Table 6.19: Anti-Diabetes Available in Prefilled Insulin Pen, 2015
  • Table 6.20: Anti- Diabetes Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 6.21: Contrast Agents Available in Prefilled Syringes, 2015
  • Table 7.1: Drugs Marketed in Prefilled Diluent Syringes
  • Table 7.2: Prefilled Syringes for Lyophilised Drugs
  • Table 7.3: Drugs Marketed in Dual/Multi-Chamber Prefilled Syringes
  • Table 8.1: Gerresheimer: Features of Gx Glass Prefilled Syringe
  • Table 8.2: Gerresheimer: Features of ClearJect Prefilled Syringe
  • Table 8.3: Features of syriQ Prefilled Syringe
  • Table 8.4: Features of syriQInjentle Prefilled Syringe
  • Table 8.5: Features of TopPac Prefilled Syringe
  • Table 8.6: Features of EZ-Fill Prefilled Syringe
  • Table 8.7: West Pharmaceutical Services: Features of Daikyo CZ Prefilled Syringe
  • Table 8.8: Manufacturing Facilities at Various Manufacturing Sites of Vetter Pharma
  • Table 9.1: PFS Component Manufacturers
  • Table 9.2: West Pharmaceutical Services: Plungers
  • Table 9.3: West Pharmaceutical Services: Manufacturing of PFS Components
  • Table 9.4: Datwlyer: Plungers
  • Table 9.5: Datwlyer: Needle Shields and Tip Caps
  • Table 10.1: Ypsomed: Comparison of Auto-Injectors
  • Table 10.2: SHL: Comparison of Auto-injectors
  • Table 10.3: Owen Mumford: Comparison of Auto-injectors
  • Table 11.1: SWOT Analysis
  • Table 11.2: Prefilled Syringe Recalls, 2003-2015,
  • Table 11.3: List of Marketed/Pipeline Needleless Injection Devices
  • Table 12.1: Seasonal Flu Vaccines in the US, 2014-2015
  • Table 12.2: Domestic Prefilled Syringe Manufacturers in China: Comparison of Product Portfolio
  • Table 12.3: Features of WeGo Glass PFS
  • Table 12.4: Drugs Approved in Prefilled Syringes Format in Japan
  • Table 12.5: Features of Glass PFS
  • Table 12.6: Features of ClearJect PFS
  • Table 12.7: Features of Rose-Fill Glass PFS
  • Table 12.8: Features of Rose-Fill Plastic PFS
  • Table 13.1: Prefilled Syringes Price Estimate (USD per unit)
  • Table 13.2: Vaccines Administered Via Prefilled Syringes
  • Table 13.3: List of Anticoagulants and Administration Route
  • Table 13.4: List of Anticoagulants Sold in Prefilled Syringes
  • Table 13.5: List of Multiple Sclerosis Drugs and Administration Route
  • Table 13.6: List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
  • Table 13.7: List of Anti-Arthritic Drugs and Administration Route
  • Table 13.8: List of Anti-Arthritic Drugs Sold in Prefilled Syringes
  • Table 13.9: List of Anti-Anaemic Drugs and Administration Route
  • Table 13.10: List of Anti-Anaemic Drugs Sold in Prefilled Syringes
  • Table 13.11: List of Other Drugs Sold in Prefilled Syringes
  • Table 13.12: List of Contrast Agents using Prefilled Syringes
  • Table 16.1: Sales of Leading Drugs Available in Prefilled Syringes, 2014 (USD Million)
  • Table 16.2: Humira Global Sales, 2003-2014 (USD Million)
  • Table 16.3: Enbrel US & Canada Sales, 2002-2014 (USD Million)
  • Table 16.4: Enbrel Outside US & Canada (EU, Japan) Sales, 2010-2014 (USD Million)
  • Table 16.5: Copaxone Sales, 2001-2014 (USD Million)
  • Table 16.6: Copaxone Unit Sales, 2000-2008: Distribution By Vials and Prefilled Syringes (Million)
  • Table 16.7: Becton Dickinson Medical: Sales, 2010-2014 (USD, Billion)
  • Table 16.8: Becton Dickinson Medical: Sales by Sub-Segments, 2014(USD Million, %)
  • Table 16.9: Gerresheimer: Sales, 2010-2014 (EUR, Million)
  • Table 16.10: Gerresheimer: Sales by Business Divisions, 2014(EUR Million, %)
  • Table 16.11: Gerresheimer: Sales by Region, 2011-2014 (EUR Million)
  • Table 16.12: Nipro Corporation: Sales, 2010-2014 (YEN Billion)
  • Table 16.13: Nipro Corporation: Sales by Business Divisions, FY2013/14 (YEN Billion, %)
  • Table 16.14: Nipro Corporation: Global Sales by Region, FY 2013/14 (YEN Billion, %)
  • Table 16.15: Nipro Corporation: Sales by Domestic Market, 2010-2014 (YEN Billion)
  • Table 16.16: SCHOTT: Sales, FY 2012/13- FY 2013/14 (EUR Billion)
  • Table 16.17: SCHOTT: Sales by Business Divisions, FY 2013/14 (EUR Million, %)
  • Table 16.18: SCHOTT: Sales by Region, FY 2013/14 (EUR Million, %)
  • Table 16.19: West Pharmaceutical Services: Sales, 2010-2014 (USD Million)
  • Table 16.20: West Pharmaceutical Services: Sales by Business Divisions, 2014 (USD Million, %)
  • Table 16.21: West Pharmaceutical Services: Delivery Systems Sales, 2010-2014 (USD Million)
  • Table 16.22: West Pharmaceutical Services: Sales by Domestic Market, 2010-2014 (USD Million)
  • Table 16.23: West Pharmaceutical Services: Global Sales by Region, 2014 (USD Million, %)
  • Table 16.24: Unilife Corporation: Sales, FY 2010/11 - FY 2013/14 (USD Million)
  • Table 16.25: Datwlyer Group: Sales, 2010-2014(CHF, Million)
  • Table 16.26: Datwlyer Group: Sales by Business Division, 2014(CHF, Million)
  • Table 16.27: Aptar Stelmi: Sales by Business Division, 2014(USD, Million)
  • Table 16.28: Ypsomed: Sales, 2010-2014 (CHF Million)
  • Table 16.29: Ypsomed: Sales by Business Division, FY 2014/15 (CHF Million, %)
  • Table 16.30: Bespak: Sales, 2010-2014 (GBP, Million)
  • Table 16.31: Domestic Prefilled Syringe Manufacturers in China - Annual Production Capacities, 2012 (Million Units)
  • Table 16.32: Shandong Weigao: Revenue from Prefilled Syringes (RMB Million), 2010-2014
  • Table 16.33: Shandong Weigao, 2014: Sales by Product Category (RMB Million, %)
  • Table 16.34: Terumo Corporation: Sales, FY 2010- FY 2014 (YEN Billion),
  • Table 16.35: Terumo Corporation: Sales by Business Divisions, FY 2014/15 (YEN Billion, %)
  • Table 16.36: Terumo Corporation: Sales by Region, FY 2014/15 (YEN Billion, %)
  • Table 16.37: Prefilled Syringes Price Curve, 2015 - 2025 (USD per unit)
  • Table 16.38: Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.39: Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.40: Prefilled Syringes for Vaccines, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.41: Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.42: Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.43: Prefilled Syringes for Vaccines, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.44: Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.45: Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.46: Prefilled Syringes for Anticoagulants, ForecastedNumber of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.47: Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.48: Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.49: Prefilled Syringes for Anticoagulants, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.50: Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.51: Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.52: Prefilled Syringes for Diabetes, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.53: Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.54: Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.55: Prefilled Syringes for Diabetes, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.56: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.57: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.58: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.59: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.60: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.61: Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.62: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.63: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.64: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.65: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.66: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.67: Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.68: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.69: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.70: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.71: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.72: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.73: Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.74: Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.75: Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.76: Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.77: Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.78: Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.79: Prefilled Syringes for Other Drug Classes, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.80: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.81: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.82: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.83: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.84: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.85: Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Sales, 2015 - 2025 (Optimistic Scenario, USD Million)
  • Table 16.86: Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Base Scenario, Millions)
  • Table 16.87: Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Conservative Scenario, Millions)
  • Table 16.88: Regional Prefilled Syringes, Forecasted Number of Units, 2015 - 2025 (Optimistic Scenario, Millions)
  • Table 16.89: Regional Prefilled Syringes, Forecasted Sales 2015 - 2025 (Base Scenario, USD Million)
  • Table 16.90: Regional Prefilled Syringes, Forecasted Sales 2015 - 2025 (Conservative Scenario, USD Million)
  • Table 16.91: Regional Prefilled Syringes, Forecasted Sales 2015 - 2025 (Optimistic Scenario, USD Million)

List of Companies:

The following companies and organisations have been mentioned in this report.

  • 1. 3S Bio Inc.
  • 2. Abbott Laboratories
  • 3. AbbVie Biotherapeutics
  • 4. Accord Healthcare Ltd.
  • 5. Adamis Pharmaceuticals Corporation
  • 6. AET Biotech
  • 7. Agila Biotech
  • 8. Aguettant
  • 9. Akorn
  • 10. Al Biosciences Inc.
  • 11. Alchemia Limited
  • 12. Alder Pharmaceuticals
  • 13. Alfamatic
  • 14. Allergan
  • 15. Almirall
  • 16. Amega Biotech
  • 17. American Nurses Association (ANA)
  • 18. Amgen
  • 19. Amphastar Pharmaceuticals
  • 20. Antares Pharma
  • 21. Aptar Pharma
  • 22. Apotex
  • 23. Arte Corporation
  • 24. AryoGen
  • 25. Aspen Group
  • 26. AstraZeneca
  • 27. Aurum Pharmaceuticals Ltd.
  • 28. Avesthagen
  • 29. AXXO
  • 30. Bang and Olufsen
  • 31. Barun Medical
  • 32. BASF Bioresearch Corporation
  • 33. Baxter
  • 34. Bayer Healthcare
  • 35. BD Rx Inc.
  • 36. Beacon Pharmaceuticals Ltd.
  • 37. Becton Dickinson
  • 38. Bespak
  • 39. Bharat Serums & Vaccines Ltd
  • 40. Biocad
  • 41. BioCND Inc.
  • 42. Biocon
  • 43. Bio Farma
  • 44. Biodel Inc.
  • 45. Biogen Idec
  • 46. Biogenomics
  • 47. Bioject
  • 48. Bioneer
  • 49. Bio Sidus SA
  • 50. Bioviz
  • 51. Bioxpress Therapeutics
  • 52. BlauFarmaceutica
  • 53. Boehringer Ingelheim Pharmaceuticals
  • 54. Bracco Diagnostics
  • 55. Bristol-Myers Squibb
  • 56. BuenderGlas
  • 57. Cadila Healthcare
  • 58. Cambridge Antibody Technology (Acquired by AstraZeneca)
  • 59. Cambridge Consultants
  • 60. Canyon Pharmaceuticals
  • 61. CDC (Centers for Disease Control and Prevention)
  • 62. Celgene
  • 63. Cellofarm
  • 64. Celltrion
  • 65. Chandra Bhagat Pharma
  • 66. Chon Kun Dang Pharmaceuticals
  • 67. Chugai Pharmaceutical Co., Ltd.
  • 68. CinnaGen
  • 69. Cipla
  • 70. CNS Therapeutics (acquired by Mallinckrodt)
  • 71. Coherus Biosciences
  • 72. Consort Medical Company
  • 73. Covidien
  • 74. CP Guojian Pharmaceutical Co. Ltd
  • 75. Credence Medsystems
  • 76. Crealta Pharmaceuticals
  • 77. CSL Biotherapies
  • 78. Daewoong Pharmaceutical Co., Ltd
  • 79. Daicel Corporation
  • 80. Daiichi Sankyo
  • 81. Daikyo Seiko
  • 82. DALI Medical Devices
  • 83. Datwyler
  • 84. Denka Seiken Co., Ltd.
  • 85. Dermira, Inc.
  • 86. Dong-A Pharma
  • 87. Dr. Lazar Laboratorio
  • 88. Dr. Reddy's Laboratories
  • 89. Eisai
  • 90. Elan Pharmaceuticals
  • 91. Elcam Medical
  • 92. Eli Lilly
  • 93. Emcure
  • 94. EMD Serono
  • 95. Enzon Pharma
  • 96. Epirus Biopharmaceutical
  • 97. European Agency of Occupational Safety and Health
  • 98. European Medicines Agency (EMA)
  • 99. European Medicines Evaluation Agency (EMEA)
  • 100. Eurofarma
  • 101. Excelsior Medical
  • 102. Eyetech Inc.
  • 103. Farmabion del Ecuador C.A
  • 104. Ferring Pharmaceuticals
  • 105. FDA
  • 106. Finox Biotech AG
  • 107. Fresenius Kabi
  • 108. Fujifilm Kyowa Kirin Biologics
  • 109. Future Injection Technologies
  • 110. GE Healthcare
  • 111. Genentech
  • 112. Gene TechnoScience
  • 113. GenorBiopharm
  • 114. Genzyme
  • 115. Gerresheimer
  • 116. Gland Pharma
  • 117. GlaxoSmithKline
  • 118. Globe Medical Tech
  • 119. Green Cross
  • 120. Guerbet
  • 121. Halozyme Therapeutics
  • 122. Hanwha Chemical
  • 123. Harvest Moon Pharma
  • 124. Haselmeier
  • 125. Helvoet Pharmaceutical
  • 126. Hikma Pharmaceuticals PLC
  • 127. Hoffman-La Roche
  • 128. Hospira
  • 129. Huahai
  • 130. ID Biomedical Corporation of Quebec
  • 131. Il-Yang Pharm. Co., Ltd
  • 132. Immunex Corporation
  • 133. Incepta Pharmaceuticals Ltd.
  • 134. Infusive Technologies LLC
  • 135. Injex
  • 136. Intas Pharma
  • 137. International Diabetes Federation Atlas
  • 138. Integrity Bio
  • 139. Ipsen
  • 140. ItalFarmaco
  • 141. Isis Innovation
  • 142. IVEK Corporation
  • 143. J&J
  • 144. J.O. Pharma Co. Ltd.
  • 145. Janssen Biotech Inc.
  • 146. Japan Synthetic Rubber
  • 147. Japanese Ministry of Health, Labour and Welfare (MHLW)
  • 148. JCR Pharmaceuticals
  • 149. JMS Co. Ltd.
  • 150. KAISHA Manufacturers
  • 151. Kaketsuken [The Chemo-Sero-Therapeutic Research Institute]
  • 152. Kaleo Inc.
  • 153. Kendall
  • 154. Kitasato Daiichi Sankyo Vaccine
  • 155. Kyowa Hakko Kirin
  • 156. Leo Pharma
  • 157. LG Life Sciences
  • 158. Liebmann Group
  • 159. Lundbeck
  • 160. LyoGo
  • 161. Mallinckrodt
  • 162. Marathon Pharmaceuticals
  • 163. Maruishi Pharmaceutical
  • 164. Medac Pharma
  • 165. Medeca Pharma
  • 166. Medex India Pvt. Ltd
  • 167. MedicalChain International Corporation
  • 168. Medical Glass
  • 169. MedImmune
  • 170. Medimop Medical Projects
  • 171. MedPro Safety Products
  • 172. Meiji Deika Pharma
  • 173. Merck & Co.
  • 174. Meridian
  • 175. MGlas AG(acquired by Nipro)
  • 176. Minapharm Pharmaceuticals
  • 177. Mitsubishi Tanabe
  • 178. Mitsui Chemicals
  • 179. Mochida Pharmaceuticals
  • 180. Momenta Pharmaceuticals
  • 181. MorphoSys
  • 182. MSD K.K.
  • 183. Mycenax Biotech Inc.
  • 184. Mylan
  • 185. Nanogen Biopharmaceuticals
  • 186. NATCO Pharma
  • 187. National Medical Products Inc.
  • 188. Nektar Therapeutics
  • 189. Neutral Glass & Allied industries
  • 190. Nippon Organon K.K.
  • 191. Nipro Corporation
  • 192. Novartis
  • 193. Novalek Pharmaceuticals Pvt. Ltd
  • 194. Novo Nordisk
  • 195. NPS Pharmaceuticals
  • 196. Nuova Ompi
  • 197. Occupational Safety and Health Administration (OSHA)
  • 198. Office of Combination Products (OCP)
  • 199. Omnikron Group
  • 200. Onco Biologics Inc.
  • 201. Ono Pharmaceuticals
  • 202. Otsuka Holdings Co. Ltd.
  • 203. Owen Mumford
  • 204. PA Consulting
  • 205. Palatin Technologies
  • 206. Pan Pharma
  • 207. Paras Biopharmaceutical
  • 208. Parenteral Drug Association (PDA)
  • 209. Pars No Tarkib
  • 210. PFEnex
  • 211. Pfizer
  • 212. Pharmaceutical Research and Manufacturers of America (PhRMA)
  • 213. Pisa
  • 214. Plas-Tech Engineering
  • 215. Polyplastics
  • 216. Probiomed
  • 217. ProJect Pharmaceutics
  • 218. Protalix Biotherapeutics
  • 219. Protein Sciences Corporation
  • 220. PT BioFarma
  • 221. Ranbaxy
  • 222. Regeneron Pharmaceuticals
  • 223. Reliance Life Sciences
  • 224. Revolutions Medical
  • 225. Rexam Pharma
  • 226. Rhône Poulenc-Rorer
  • 227. RheimMinapharm
  • 228. RoseLabs
  • 229. SafeShot Technologies
  • 230. Safety Syringes
  • 231. Samsung Bioepsis
  • 232. Sandoz
  • 233. Sanofi Aventis
  • 234. Sanofi Pasteur
  • 235. Schering-Plough
  • 236. Schott
  • 237. Sciele Pharma
  • 238. Serum Institute of India
  • 239. Shandong Pharmaceutical Glass Co., Ltd.
  • 240. Shandong Weigao
  • 241. Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
  • 242. Shanghai Celgen Bio-Pharmaceutical
  • 243. Shantha Biotech
  • 244. Shire
  • 245. SHL Medical
  • 246. SiO2 Medical Products
  • 247. Solvay Pharmaceuticals B.V
  • 248. StadaArzneimittel AG
  • 249. Stelmi
  • 250. Stevanato Group
  • 251. Stiefel (a GSK Company)
  • 252. Strides
  • 253. Sun Pharma
  • 254. Suzuken Co. Ltd.
  • 255. Swedish Orphan Biovitrum AB
  • 256. Taisei Kako
  • 257. Taj Pharmaceuticals
  • 258. Takeda
  • 259. Talecris Biotherapeutics
  • 260. TechnoPharm
  • 261. Teijin Pharma Ltd.
  • 262. Terumo Corporation
  • 263. Teva Pharmaceuticals
  • 264. The Medical House(Acquired by Consort Medical)
  • 265. The Medicines Company
  • 266. The Research Foundation for Microbial Diseases of Osaka University
  • 267. The Tech Group (acquired by West Pharma)
  • 268. Ticona
  • 269. Tip-Top
  • 270. Tolmar
  • 271. TriboFilm Research
  • 272. Triveni Polymers(acquired by Gerresheimer)
  • 273. Troikaa Pharma
  • 274. TSH Biopharm Corporation Ltd.
  • 275. UCB
  • 276. UNICEF
  • 277. Unilife Corporation
  • 278. Unimed Del Peru SA
  • 279. US Medical Instruments Inc.
  • 280. USPTO
  • 281. Valeant Pharmaceutical International
  • 282. Valeritas
  • 283. Vedat (acquired by Gerresheimer)
  • 284. Vetter Pharma
  • 285. Virchow Biotech Private Ltd.
  • 286. ViroPro
  • 287. Watson Pharma
  • 288. West Pharmaceutical Services, Inc.
  • 289. WHO
  • 290. Wyeth
  • 291. YangZhong Wealth Metal Co., Ltd.
  • 292. Youlyy Industrial Co., Ltd.
  • 293. Ypsomed
  • 294. Zealand Pharma
  • 295. Zeon Chemicals
  • 296. Zhejiang Hisun Pharma
  • 297. Zhejiang Xinkang Pharmaceutical Glass Co. Ltd.
  • 298. Zogenix
  • 299. ZydusCadila
  • 300. ZymoGenetics Inc.
Back to Top